Every material Form 8-K Spero Therapeutics, Inc. has filed with the SEC since August 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Spero Therapeutics announced that Chief Operating Officer Timothy Keutzer will retire effective December 31, 2026, after 11 years with the company. He is expected to serve as a consultant through approximately February 28, 2027 to support the leadership transition.
Timothy Keutzer, Chief Operating Officer, retires effective December 31, 2026
Consulting arrangement expected to run until approximately February 28, 2027, terminable by either party on fifteen days' written notice
Keutzer will be paid an hourly rate during the consulting period; the filing gives no dollar figure
Spero Therapeutics entered an at-the-market share sale agreement with Jefferies LLC as agent on August 28, 2026, allowing it to sell common stock up to $100 million once its $300 million universal shelf registration statement is declared effective. The company also terminated its prior Cantor Fitzgerald at-the-market agreement effective the same day, with no termination penalties and no shares sold under that agreement in fiscal 2024 or 2025. Shareholders could face dilution if the company sells shares under the new agreement, but the filing states no amount has been sold and no sales can occur until the registration is effective.
Agreement with Jefferies allows sales of up to $100 million of common stock under the prospectus once the registration statement is effective
Jefferies compensation is up to 3.0% of gross proceeds from shares sold
Shelf registration on Form S-3 covers up to $300 million in debt securities, common stock, preferred stock and other securities
Cantor Fitzgerald sales agreement terminated effective August 28, 2026, with no termination penalties and no shares sold in fiscal 2024 or 2025
Spero Therapeutics reported a second-quarter 2026 net loss of $9.6 million, or $0.16 per share, compared with a net loss of $1.7 million, or $0.03 per share, a year earlier. The company recognized no revenue in the quarter, versus $14.2 million in the second quarter of 2025, and said it expects cash plus the July 2026 royalty financing to fund operations into the second half of 2029.
Q2 2026 total revenue was zero, compared with $14.2 million in Q2 2025, as deferred and grant revenue had been fully recognized in prior periods.
Q2 2026 research and development expense was $3.4 million, down from $10.7 million; general and administrative expense rose to $6.5 million from $5.9 million.
Cash and cash equivalents were $50.8 million at June 30, 2026, before the $105 million royalty financing closed in July 2026.
Other events disclosed include the July 2026 exclusive license for SP001 from Innovent Biologics and the appointment of Debra Jeske Zack as Chief Medical Officer.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Spero Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →